CSL Limited (ASX:CSL)
153.72
+0.98 (0.64%)
Feb 19, 2026, 12:21 PM AEST
CSL Limited Revenue
CSL Limited had revenue of $8.33B USD in the half year ending December 31, 2025, with 3.46% growth. This brings the company's revenue in the last twelve months to $15.41B, up 1.16% year-over-year. In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B with 5.12% growth.
Revenue (ttm)
$15.41B
Revenue Growth
+1.16%
P/S Ratio
3.19
Revenue / Employee
$515.22K
Employees
29,904
Market Cap
73.58B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
| Clinuvel Pharmaceuticals | 95.02M |
| Mesoblast | 26.23M |
| PYC Therapeutics | 23.49M |
| Clarity Pharmaceuticals | 9.46M |
| Orthocell | 7.55M |
| Racura Oncology | 6.04M |
CSL Limited News
- 7 hours ago - Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo - Benzinga
- 7 days ago - Half Year 2026 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 7 days ago - CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 8 days ago - CSL Limited (CSLLY) Discusses Leadership Transition and Appointment of Interim CEO Transcript - Seeking Alpha
- 21 days ago - CSL Limited: Upside Potential Is Strong From These Levels But I Remain Cautious - Seeking Alpha
- 22 days ago - Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited - Business Wire
- 2 months ago - Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years - PRNewsWire
- 3 months ago - CSL Limited (CSLLY) Commits $1.5B to Expand U.S. Operations - GuruFocus